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Clopidogrel in unstable angina: ‘Clear benefit
with an acceptable safety risk’
Clopidogrel, in addition to standard medications, confers
significant benefits to patients with acute coronary syn-
dromes. Salim Yusuf (McMaster University, Hamilton,
Canada) presented results from CURE (Clopidogrel in
Unstable Angina to Prevent Recurrent Ischemic Events)
study for the first time. Compared with placebo, clopido-
grel was shown to reduce, by 20%, the risk of cardiovas-
cular death, myocardial infarction, and stroke in patients
with acute coronary syndrome (ACS).
Clopidogrel is an advanced antiplatelet agent that works by
direct blockade of adenosine diphosphate receptors. It is
currently indicated for the prevention of atherosclerotic
events in patients with atherosclerotic disease, documented
by recent myocardial infarction (MI) or ischemic stroke, or
peripheral arterial disease. The CURE study involved
12,562 patients in 28 countries and ran from December
1998 to December 2000. “It provides important new find-
ings that constitute a major step forward and could lead to
a very significant improvement in the treatment of patients
at risk of heart attack, stroke, and cardiovascular death”
said Yusuf.
In the study, subjects who were admitted to hospital with
suspected ACS were given aspirin (75–325 mg/day) then
randomised to receive either clopidogrel (75 mg/day) or
placebo. Subjects also received an initial loading dose of
clopidogrel 300 mg orally (or matching placebo) within
24 hours of symptom onset. Treatment was continued for
three months to one year, and the primary endpoint was a
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Abstract
The recent scientific session of the American College of Cardiology (ACC), held in Orlando, provided
a forum for ongoing cardiovascular clinical trials from around the world. The high point was clearly the
first ever release of results from the CURE study. The Late-Breaking Clinical Trials sessions also
featured results and interim data from other trials such as MIRACLE, CAPRICORN, SVG WRIST,
RITZ 2, SoS, and PRINCE. New applications for data from the OPUS-TIMI 16 trial were discussed
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further studies.
Keywords: cardiology, clinical trials, congress, meeting report
Received: 2 April 2001
Accepted: 6 April 2001
Published: 11 April 2001
Curr Control Trials Cardiovasc Med 2001, 2:85–89
© 2001 BioMed Central Ltd
(Print ISSN 1468-6708; Online 1468-6694)
ACE = angiotensin converting enzyme; ACS = acute coronary syndrome; ADHF = acute decompensated heart failure; AGE = advanced glycosy-
lated crosslink endproducts; CAPRICORN = Carvedilol Post Infarction Survival Control in Left Ventricular Dysfunction; CI = cardiac index; CRP =
C-reactive protein; CRT = cardiac resynchronisation therapy; CURE = Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events;
CVD = cardiovascular death; HF = heart failure; ISR = in-stent restenosis; LV = left ventricular; MI = myocardial infarction; MIRACLE = Multicenter
InSync Randomized Clinical Evaluation; NYHA = New York Heart Association; OPUS = Orbofiban in Patients with Unstable Coronary Syndromes;
PCI = percutaneous coronary intervention; PRINCE = Pravastatin Inflammation CRP Evaluation; PTCA = percutaneous transluminal coronary angio-
plasty; RITZ = Randomised Intravenous Tezosentan; RR = relative risk; SoS = Stent or Surgery; SVG = saphenous vein bypass grafts; SVG
WRIST = Washington Radiation for In-Stent Restenosis Trial; TIMI = Thrombolysis in Myocardial Infarction.Current Controlled Trials in Cardiovascular Medicine    Vol 2 No 2 Lyford
composite of MI, stroke (any type), cardiovascular death
(CVD), and refractory ischemia.
Treatment with clopidogrel was found to confer a risk
reduction of 20% on the composite endpoint, at a highly
significant P = 0.00005. This benefit was incremental and
independent of concomitant drug treatment and revascu-
larization. Importantly, high and low risk patients showed a
similar reduction in events. Also, the effects on the end-
points became apparent within two hours and continued to
30 days and beyond. The major side effect was bleeding,
which was independent of dose. The incidence of major
bleeding increased by 30% in the treatment group (similar
to aspirin), while the incidence of life-threatening bleeding
increased by 15% (non-significant). Yusuf felt the risk-
benefit ratio, both early and late, was ‘favourable’ and the
side-effect profile was ‘acceptable’ and far outweighed by
the savings in lives and cardiac events.
The widespread use of clopidogrel in addition to aspirin in
ACS could prevent about 50,000–100,000 heart attacks
or deaths every year in North America. Over the study
duration, the investigators found the drug was ‘cost-
neutral’ and, compared with percutaneous transluminal
coronary angioplasty (PTCA) and glycoprotein IIb/IIIa
blockers, was cost-saving.
Cardiac resynchronisation in HF confers
‘clinically and statistically meaningful’ benefit
A new type of pacemaker has shown ‘markedly positive’
results in patients with heart failure. Results from
MIRACLE (Multicenter InSync Randomized Clinical Evalu-
ation), a large, randomized, double-blind study, were
reported by William Abraham (University of Kentucky
College of Medicine, Lexington, USA). He presented six-
month clinical, functional, and quality of life data.
Cardiac resynchronisation therapy (CRT) is an innovative
methodology to resynchronise the heart, in which a left
ventricular (LV) lead is placed into a cardiac vein via the
coronary sinus. After promising pilot studies, MIRACLE
was designed to evaluate CRT in patients with heart
failure (HF), complicated with intraventricular conduction
delays or ventricular dysynchrony. In all, 266 patients were
enrolled at 44 centres in the USA and Canada. To ensure
blinding, the device was implanted in all patients, but only
half were switched on.
Overall, the implant success rate was 93%, “far exceeding
expectations,” Abraham said. There were statistically sig-
nificant improvements in all primary and secondary end-
points compared with the control group. In particular,
more patients had an improvement of at least 1 New York
Heart Association (NYHA) class (69% vs 44%). Active
treatment also improved a combined endpoint, improve-
ment in NYHA ³1 class and six minute walk ³50 meters,
which was achieved by 41% of the CRT group versus
15% in the controls (P < 0.001). Patients who received
the active device were also more likely to show improved
quality of life (47% vs 22%, P < 0.001) and reduced QRS
duration (P < 0.001).
Other clinical measures – LV dimensions and function,
peak VO2 and plasma norepinephrine – showed signifi-
cant benefits with active treatment versus control. Cost-
effectiveness analyses showed that CRT is associated
with significant reductions in healthcare utilisation, while
the application of a composite outcome measure also
favoured the device over placebo. No long-term deleteri-
ous effects of CRT have been seen so far and it was
stressed that the results were clinically and statistically
meaningful. Abraham predicted that CRT could potentially
benefit 0.75 to 1.5 million patients in the United States.
CAPRICORN: Carvedilol saves lives and
reduces risk of second MI
Carvedilol offers ‘dramatic’ protection against death and
second MI in patients with postinfarction left ventricular
dysfunction. Results presented from the CAPRICORN
(Carvedilol Post Infarction Survival Control in Left Ventric-
ular Dysfunction) trial show that treating post-MI patients
with the beta-blocker carvedilol reduces the risk of another
MI by 41% and the risk of dying by 23%. Data firmly
support the addition of carvedilol to standard therapy in MI
patients. Lead author Henry Dargie (University of
Glasgow, UK) commented: “Until now, we have had little
evidence to determine the additional benefits of beta
blockers used in combination with modern standard
therapy in patients with acute MI and confirmed LV sys-
tolic dysfunction and/or clinical evidence of heart failure.”
CAPRICORN is the first large multicentre placebo-con-
trolled study to examine beta blockade post-MI, since the
widespread introduction of thrombolytics and angiotensin
converting enzyme (ACE) inhibitors. It is also the first trial
to focus on a population with postinfarction LV dysfunc-
tion, regardless of clinical evidence of heart failure. A total
of 1,959 patients in over 160 sites in 17 countries, were
prospectively enrolled within 21 days of suffering an MI
and randomly assigned to either carvedilol or placebo.
Since CAPRICORN was an event-driven study, follow-up
stopped in March 2000 when the predefined number of
endpoints (633) had occurred. The co-primary endpoints
were all-cause mortality/ cardiovascular hospitalisation
and all-cause mortality; secondary endpoints were sudden
death and hospitalisation for HF.
Treatment with carvedilol reduced the risk of all-cause
death from 15 to 12% (P = 0.031). This represents a 23%
relative risk reduction in mortality and was associated with
a 41% (P = 0.014) reduction in risk of recurrent non-fatal
MI and a 29% (P = 0.002) reduction in the risk of all-causec
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mortality or non-fatal MI. As in previous trials, carvedilol was
well-tolerated, with 75% of patients being uptitrated to the
maximum dose (25 mg twice daily) by four weeks.
Dargie described the implications of the CAPRICORN
results for clinical practice as ‘clear and far reaching’.
Based on this data he said: “Carvedilol should be consid-
ered in all patients following MI with significant LV dys-
function. The results are extremely good news for patients
in terms of markedly reduced chance of additional heart
attacks and greater likelihood of survival.”
Intracoronary gamma radiation ‘safe and
effective’ for in-stent restenosis
Ron Waksman (Washington Hospital Center, Washington
DC, USA) presented results from SVG WRIST (Washing-
ton Radiation for In-Stent Restenosis Trial). This is the first
multicentre double-blind randomised trial to examine the
usefulness of gamma radiation in patients who have devel-
oped diffuse in-stent restenosis following coronary artery
bypass surgery. Gamma radiation is already approved for
the treatment of in-stent restenosis (ISR) in native coronar-
ies, but these results support the extension of this therapy
to patients with in-stent restenosis in saphenous vein
bypass grafts (SVG). 
SVG WRIST involved 120 patients with angina and
diffuse ISR in SVGs. Subjects were aged 65–67 and
almost all had hyperlipidemia and hypertension. All
patients initially underwent PTCA with laser ablation,
atherectomy, or stenting, before randomisation to receiv-
ing either 192Ir-labelled seeds or placebo. Radiation (14 or
15 Gy) was delivered for a mean dwell time of 22 ± 0.7
minutes, and was well tolerated. 
At 30 days, no adverse events related to radiation therapy
had occurred. At six months, the restenosis rate was signifi-
cantly lower in the radiation group compared with the
placebo group (16% vs 43%, P = 0.004). Radiation therapy
reduced by 78% the need for repeat revascularization; only
10% of the irradiated patients required further intervention,
versus 48% in the placebo group (P = 0.001). The rate of
major cardiac events (death, MI) was lower in the gamma
radiation group (20%) than in the placebo group (55%);
P = 0.001. Finally, radiation therapy was associated with a
reduction in late thrombosis (1.7% vs 6.7%) with no excess
of edge effect compared with control.
Conventional treatment of ISR in bypass grafts is associ-
ated with a high recurrence rate however, Waksman con-
cluded that the SVG WRIST study demonstrated that
catheter-based radiation therapy was safe and effective
for the reduction of the overall restenosis rate, and the
need for repeat revascularization. These results support
expanding the indications for gamma radiation therapy to
patients with ISR following bypass grafting.
Endothelin receptor antagonist stabilises
acute HF without inducing arrhythmias
Patients with acute decompensated heart failure (ADHF)
gain substantial benefits from rapid administration of
tezosentan, a potent intravenous dual endothelin receptor
antagonist.
Guillermo Torre-Amione (Baylor College of Medicine,
Houston, USA) presented results from the Randomised
Intravenous Tezosentan (RITZ) 2 study. It suggests that
tezosentan not only improves hemodynamic variables but
also confers benefit on clinical parameters such as
dyspnea and death. There have been few, if any, major
advancements in the treatment of acute HF during the last
decade but it was felt that tezosentan may offer a new
approach to treating this disease. Torre-Amione described
the data as ‘compelling’ but cautioned that the study was
not designed to assess clinical endpoints. These will be
provided by RITZ 1, a 650-patient study evaluating the
drug’s ability to relieve the symptoms of congestive heart
failure. RITZ 4 and 5 will complete the program as sup-
porting studies.
In RITZ 2, 292 patients at 32 centres in the USA, Europe,
and Israel were randomised to receive either tezosentan
50 mg/h or 100 mg/h or placebo for 24 hours after admis-
sion for ADHF. The study’s primary endpoint was the
change in cardiac index (CI) six hours after the start of
treatment, while secondary endpoints included other
hemodynamic variables, dyspnea, time to death, and wors-
ening of HF at 24 hours.
Both doses of tezosentan improved CI and pulmonary
capillary wedge pressure significantly more than placebo
(P < 0.0001). The effect was maintained for the duration
of treatment and for at least six hours thereafter. Tezosen-
tan was also associated with a dose-related decrease in
arterial pressure, and, importantly, no changes in heart
rate. In terms of clinical benefit, patients who received
active treatment were less likely to experience a worsening
in dyspnea, and more likely to have an improvement
(P = 0.048 and nonsignificant, respectively). In addition, a
clear tendency for improvement in time to worsening of HF
or death was observed over the 24 hours of treatment
with tezosentan (P = 0.06) compared with placebo.
The safety profile was generally favourable, with no differ-
ence in the incidence of serious adverse events up to
28 days after treatment. Patients in the treatment group
were more likely to experience headaches and sympto-
matic hypotension, although this was experienced only at
the higher dose. Torre-Amione stated that the R&D efforts
would now concentrate on the 50 mg/hr dose, which had
a safety profile similar to placebo. “When treating patients
with acute HF, every second counts,” he added. “Quickly
improving the heart’s pumping ability can prevent the
Available online http://cvm.controlled-trials.com/content/2/2/085patient from becoming sicker, which may lead to conges-
tive HF, or even death.”
Inclusion of troponin status improves
accuracy of TIMI Risk Score
Troponin testing only identifies around half of patients pre-
senting with acute coronary syndromes who are at high
risk of mortality. Data presented suggest that, while tro-
ponin testing is not a definitive tool for risk stratification in
patients with ACS, it provides useful additional information
about patients who warrant aggressive therapy.
Lead investigator Christopher Cannon (Brigham and
Women’s Hospital, Boston, USA) presented the new
data, which comes from Orbofiban in Patients with Unsta-
ble Coronary Syndromes-TIMI (OPUS-TIMI) 16 trial. He
explained that, while patients who are troponin-positive are
known to be at high risk of mortality and recurrent cardiac
events, there is debate about patients who are troponin-
negative. OPUS-TIMI 16 used a case-control design and a
composite endpoint (death, MI, urgent revascularization,
recurrent ischemia, stroke) to test whether all patients who
are troponin-negative are at low risk. Levels of troponin I
were measured in 2,241 patients on hospital admission
and converted into a Thrombolysis in Myocardial Infarction
(TIMI) Risk Score.
As expected, a positive troponin test was associated with
a significantly increased relative risk (RR) of all endpoints
at 10 months (RR 1.6-1.82), but only weakly for the com-
posite endpoint including angina requiring hospitalisation.
Among patients who were troponin-negative (£0.1 ng/ml),
the TIMI Risk Score identified a graded increase in the rel-
ative risk of the composite endpoint to 10 months.
Patients who scored 0 had a RR of 1, while a score of 6
had a RR of 2.6 (P for trend = 0.002).
Cannon said that the incorporation of troponin tests into
routine risk-stratification of patients with suspected MI
would both improve diagnosis and facilitate early, aggres-
sive medical therapy. He also noted that the number of
lives saved offsets the cost of testing.
PRINCE: Inflammation in atherosclerosis a
‘very real phenomenon’
Paul Ridker (Brigham and Women’s Hospital, Harvard
Medical School, Boston, USA) announced results from
PRINCE (Pravastatin Inflammation CRP Evaluation).
Pravastatin was associated with a highly significant reduc-
tion in C-reactive protein (CRP) levels becoming apparent
at four weeks and present for the duration of the study.
PRINCE had two tiers: an open-label evaluation of pravas-
tatin 40 mg/day in 898 patients with known CVD (sec-
ondary prevention cohort) and a double-blind trial of
pravastatin 40 mg versus placebo in 1,339 apparently
healthy men and women (primary prevention cohort). In
both groups, pravastatin reduced median CRP levels by
13.2% (P < 0.001), while no change was observed with
placebo. The effect was independent of gender, age,
smoking status, body mass index, baseline lipid levels, and
the presence of diabetes. Stratification of CRP response
according to lipid levels revealed no association with
either baseline or final LDL cholesterol (LDL-C).
In addition to the primary findings, the PRINCE study
results also provides physicians with additional information
that can be useful in evaluating patients in everyday prac-
tice. The study demonstrated that the reduction in CRP
levels was similar in magnitude among patients with and
without a history of heart disease. The investigators found
it intriguing that the reductions in CRP levels were mini-
mally related to changes in LDL cholesterol levels. Inflam-
matory processes are thought to be critical in driving the
progression of atherosclerosis, as well as predisposing
plaques to rupture. However, it is not known yet if reduc-
ing CRP itself reduces heart risk. This is a key question for
the future. Ridker emphasised that lipid-lowering strate-
gies are underused in both the USA and Europe, and
hoped that these results would encourage more wide-
spread, and more aggressive, use of statins.
In response to a question regarding the biological basis of
these results, Ridker admitted that there are no clear-cut
answers at present. He speculated that, while changes in
CRP are not directly linked to changes in LDL-C, this
could be a surrogate for changes in oxidised LDL-C –
which cannot be measured. The data suggest that several
pathways are involved, one or more of which may be a
direct anti-inflammatory route. He admitted that although
statins are known to decrease cholesterol levels and cho-
lesterol drives the response to vascular injury, separating
the two processes is difficult. Finally, Ridker highlighted
another paradox: statins are known to reduce the risk of
stroke, but LDL-C is not a risk factor for this condition.
Results from other trials are needed to confirm or refute
the hypothesis that lowering CRP levels reduces the risk
of thrombotic events.
Experimental drug lowers BP, improves
vascular compliance
David Kass (Johns Hopkins University, Baltimore, USA)
presented data on an experimental drug ALT-711, which
has shown promising results in a small trial of patients with
age-related vascular stiffening.
Vascular stiffening and the associated increase in pulse
pressure and systolic blood pressure is a huge epidemio-
logical problem, affecting about half of all individuals aged
over 60 years. ALT-711 may represent a novel therapeutic
approach for patients with arterial stiffness associated
with ageing, diabetes, and systolic hypertension.
Current Controlled Trials in Cardiovascular Medicine    Vol 2 No 2 LyfordIn the study, the oral compound, ALT-711, or matching
placebo were given to 93 patients with systolic blood
pressure  ³140 mmHg and evidence of vascular stiffening.
After eight weeks, patients who received the active com-
pound had a significant reduction in arterial pulse pres-
sure. These patients also showed an improvement in
vascular compliance of up to 18%.
Previous drugs to treat this common blood pressure
abnormality have mostly focused on lowering the mean or
average pressure by relaxing the peripheral resistance
arteries, but Kass’s results showed that ALT-711 appears
to be different. It appeared to act on the larger vessels that
regulate stiffness.
ALT-711 works by breaking advanced glycosylated
crosslink endproducts (AGE) that form between proteins.
The crosslinks particularly target proteins that are long-
lived, such as structural proteins in the artery wall that
confer the ability to stretch. In the cardiovascular system,
AGE results in a loss of elasticity, which in turn causes
raised pulse pressure (a major risk factor for atherosclero-
sis and vascular disease) and increases the heart’s work-
load (a risk factor for MI, heart failure, and coronary artery
disease).
The results of this study has paved the way for a major
multicentre clinical trial involving hundreds of patients with
age-related vascular stiffening.
Surgery has slight advantage over stenting –
but data are inconclusive
One-year results from the Stent or Surgery (SoS) trial, pre-
sented by Rodney Stables (Royal Liverpool University
Hospital, UK), show a slight advantage for bypass surgery
over stenting. Surprisingly, there appears to be a mortality
advantage in patients managed with bypass. The mortality
rate was 1.2% with CABG versus 4.1% with angioplasty.
In the SoS trial, 988 patients with multivessel coronary
disease were recruited at 53 centres in Europe and
Canada. They were randomised in equal proportion to
initial therapy with CABG or percutaneous coronary inter-
vention (PCI) and stent implantation. All patients were fol-
lowed for at least one year, with an average follow-up of
two years. Dr Stables reported that both procedures were
associated with low rates of major adverse cardiac events
(death, MI, and repeat revascularization). The rate of the
combined endpoint, death and nonfatal MI, was similar in
the two groups, at 9.5%.
Dr Stables said the mortality advantage seen with CABG
was ‘surprising’ and cautioned that since the overall death
rate in this group was extremely low at 0.8%, the results
are prone to skew. He labelled this figure ‘extremely
unusual’ and ‘out of step with other clinical trials in the
area’, and stressed that SoS was not designed to assess
mortality as a primary endpoint. In addition, there was an
unusually high number of carcinoma-related deaths in the
angioplasty group compared with the surgery group,
which could have further distorted the data.
Continuing analysis of the SoS data will provide informa-
tion about healthcare costs and cost-benefit, patient-
reported symptoms, and quality of life. In particular, Dr
Stables said that neuropsychological outcomes are due to
be assessed in a sub-study (n = 172) where cerebral
function will be tested at baseline, 6, and 12 months.
“Only then will we know the true role of PCI in revascular-
ization in the multivessel arena,” Stables stressed. These
results are due to be presented at the European Society
for Cardiology’s meeting later this year.
Available online http://cvm.controlled-trials.com/content/2/2/085
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